Logo image of ALBO

ALBIREO PHARMA INC (ALBO) Stock Fundamental Analysis

USA - NASDAQ:ALBO - US01345P1066 - Common Stock

44.15 USD
-0.1 (-0.23%)
Last: 3/2/2023, 8:00:01 PM
44.33 USD
+0.18 (+0.41%)
After Hours: 3/2/2023, 8:00:01 PM
Fundamental Rating

4

Overall ALBO gets a fundamental rating of 4 out of 10. We evaluated ALBO against 538 industry peers in the Biotechnology industry. While ALBO seems to be doing ok healthwise, there are quite some concerns on its profitability. ALBO shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALBO has reported negative net income.
ALBO had a negative operating cash flow in the past year.
ALBO Yearly Net Income VS EBIT VS OCF VS FCFALBO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M -100M

1.2 Ratios

ALBO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALBO Yearly ROA, ROE, ROICALBO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -20 -40 -60

1.3 Margins

ALBO has a better Gross Margin (95.56%) than 95.92% of its industry peers.
The Profit Margin and Operating Margin are not available for ALBO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.56%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALBO Yearly Profit, Operating, Gross MarginsALBO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200 -400 -600 -800 -1K

More info and screens

6

2. Health

2.1 Basic Checks

ALBO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALBO has more shares outstanding
Compared to 1 year ago, ALBO has an improved debt to assets ratio.
ALBO Yearly Shares OutstandingALBO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M
ALBO Yearly Total Debt VS Total AssetsALBO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of 0.32, we must say that ALBO is in the distress zone and has some risk of bankruptcy.
ALBO has a Altman-Z score (0.32) which is in line with its industry peers.
ALBO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.32
ROIC/WACCN/A
WACC9.04%
ALBO Yearly LT Debt VS Equity VS FCFALBO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M -100M 150M

2.3 Liquidity

ALBO has a Current Ratio of 6.32. This indicates that ALBO is financially healthy and has no problem in meeting its short term obligations.
ALBO has a Current ratio (6.32) which is comparable to the rest of the industry.
ALBO has a Quick Ratio of 6.23. This indicates that ALBO is financially healthy and has no problem in meeting its short term obligations.
ALBO has a Quick ratio of 6.23. This is comparable to the rest of the industry: ALBO outperforms 53.13% of its industry peers.
Industry RankSector Rank
Current Ratio 6.32
Quick Ratio 6.23
ALBO Yearly Current Assets VS Current LiabilitesALBO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M 200M 250M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.52% over the past year.
The Revenue has grown by 432.29% in the past year. This is a very strong growth!
Measured over the past years, ALBO shows a very strong growth in Revenue. The Revenue has been growing by 47.13% on average per year.
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
Revenue 1Y (TTM)432.29%
Revenue growth 3Y47.13%
Revenue growth 5YN/A
Sales Q2Q%168.34%

3.2 Future

The Earnings Per Share is expected to grow by 24.17% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 84.10% on average over the next years. This is a very strong growth
EPS Next Y-20.91%
EPS Next 2Y0.48%
EPS Next 3Y13.05%
EPS Next 5Y24.17%
Revenue Next Year69.42%
Revenue Next 2Y72.94%
Revenue Next 3Y92.77%
Revenue Next 5Y84.1%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ALBO Yearly Revenue VS EstimatesALBO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
ALBO Yearly EPS VS EstimatesALBO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALBO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALBO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALBO Price Earnings VS Forward Price EarningsALBO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALBO Per share dataALBO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

ALBO's earnings are expected to grow with 13.05% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.48%
EPS Next 3Y13.05%

More info and screens

0

5. Dividend

5.1 Amount

ALBO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALBIREO PHARMA INC

NASDAQ:ALBO (3/2/2023, 8:00:01 PM)

After market: 44.33 +0.18 (+0.41%)

44.15

-0.1 (-0.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2023-02-27
Earnings (Next)05-15 2023-05-15
Inst Owners0%
Inst Owner Change0%
Ins Owners0.73%
Ins Owner Change0%
Market Cap915.89M
Analysts76.92
Price Target42.84 (-2.97%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-49.7%
Min EPS beat(2)-78.3%
Max EPS beat(2)-21.09%
EPS beat(4)1
Avg EPS beat(4)-14.16%
Min EPS beat(4)-78.3%
Max EPS beat(4)58.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.45%
Min Revenue beat(2)0.99%
Max Revenue beat(2)7.92%
Revenue beat(4)3
Avg Revenue beat(4)37.1%
Min Revenue beat(4)-15.88%
Max Revenue beat(4)155.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.11%
PT rev (3m)-28.41%
EPS NQ rev (1m)-7.4%
EPS NQ rev (3m)-7.4%
EPS NY rev (1m)-1.4%
EPS NY rev (3m)-17.75%
Revenue NQ rev (1m)-0.45%
Revenue NQ rev (3m)-0.4%
Revenue NY rev (1m)-1.08%
Revenue NY rev (3m)-0.96%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 15.96
P/FCF N/A
P/OCF N/A
P/B 9.15
P/tB 11.06
EV/EBITDA N/A
EPS(TTM)-6.72
EYN/A
EPS(NY)-6.71
Fwd EYN/A
FCF(TTM)-5.61
FCFYN/A
OCF(TTM)-5.56
OCFYN/A
SpS2.77
BVpS4.82
TBVpS3.99
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.56%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 223.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.32
Quick Ratio 6.23
Altman-Z 0.32
F-Score3
WACC9.04%
ROIC/WACCN/A
Cap/Depr(3y)209.07%
Cap/Depr(5y)244.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
EPS Next Y-20.91%
EPS Next 2Y0.48%
EPS Next 3Y13.05%
EPS Next 5Y24.17%
Revenue 1Y (TTM)432.29%
Revenue growth 3Y47.13%
Revenue growth 5YN/A
Sales Q2Q%168.34%
Revenue Next Year69.42%
Revenue Next 2Y72.94%
Revenue Next 3Y92.77%
Revenue Next 5Y84.1%
EBIT growth 1Y7.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-35.31%
OCF growth 3YN/A
OCF growth 5YN/A